• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

  Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-01-27)

  BACKGROUND:Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
• From patent to patient: analysing access to innovative cancer drugs. 

  Sharpe, E; Hoey, R; Yap, C; Workman, P (2020-01-27)

  Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from 6 ...
• Genomics of lethal prostate cancer at diagnosis and castration-resistance. 

  Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petremolo, A; Zafeiriou, Z; Fontes, MS; Perez-Lopez, R; Tunariu, N; Fulton, BA; Jones, R; McGovern, UB; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2019-12-24)

  Genomics of primary prostate cancer differs from that of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, also ...
• Optimising trial methodologies to maximise trial efficiencies: a case study in breast cancer radiotherapy trials 

  Bhattacharya, I (2020-01-31)

  Background: In an era of falling local relapse rates, the risk-benefit ratio of adjuvant breast radiotherapy requires careful consideration, and the collection of normal tissue effect (NTE) data optimised. For patients at ...
• Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation. 

  Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; Dearnaley, D; Gulliford, S; CHHiP Trial Management Group (2020-01-24)

  BACKGROUND:The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based ...
• Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. 

  Murray, J; Gulliford, S; Griffin, C; Wilkins, A; Syndikus, I; Staffurth, J; Panades, M; Scrase, C; Parker, C; Khoo, V; Dean, J; Mayles, H; Mayles, P; Thomas, S; Naismith, O; Mossop, H; Cruickshank, C; Hall, E; Dearnaley, D; CHHiP Investigators (2020-03)

  Background and purpose:The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms ...
• Phospho-proteomics and functional genomics for the characterisation of resistance mechanisms to agents targeting the EGFR, PI3K and MAPK pathways and their application in guiding drug combinations in colorectal cancer 

  Georgiou, A (2019-12-31)

  KRAS mutant and RAS/BRAF wild type (RAS WT) colorectal cancer (CRC) cells respond differently to targeted agents, as exemplified by cetuximab, an anti-EGFR antibody, which is only effective in a proportion of patients with ...
• Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. 

  Chamberlain, FE; Wilding, C; Jones, RL; Huang, P (2019-06)

  Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ...
• Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. 

  Coombes, RC; Kilburn, LS; Tubiana-Mathieu, N; Olmos, T; Van Bochove, A; Perez-Lopez, FR; Palmieri, C; Stebbing, J; Bliss, JM (2016-06)

  BACKGROUND:The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node ...
• Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. 

  Poudel, P; Nyamundanda, G; Patil, Y; Cheang, MCU; Sadanandam, A (2019-01)

  Breast cancer is a highly heterogeneous disease. Although differences between intrinsic breast cancer subtypes have been well studied, heterogeneity within each subtype, especially luminal-A cancers, requires further ...
• The Impacts of Bladder Cancer on UK Healthcare Costs and Patients’ Health-Related Quality of Life: Evidence from the BOXIT Trial 

  Hall, E; Porta, N
• Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification. 

  Tovey, H; Cheang, MCU (2019-11-25)

  The concept of precision medicine has been around for many years and recent advances in high-throughput sequencing techniques are enabling this to become reality. Within the field of breast cancer, a number of signatures ...
• Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT). 

  Lidington, E; McGrath, SE; Noble, J; Stanway, S; Lucas, A; Mohammed, K; van der Graaf, W; Husson, O (2020-01-15)

  BACKGROUND:There are a growing number of mHealth tools for breast cancer patients but a lack of scientific evidence for their effects. Recent studies have shown a mix of positive and negative impacts on users. Here we will ...
• Biomarker-guided trials: Challenges in practice. 

  Antoniou, M; Kolamunnage-Dona, R; Wason, J; Bathia, R; Billingham, C; Bliss, JM; Brown, LC; Gillman, A; Paul, J; Jorgensen, AL (2019-12)

  Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been ...
• Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. 

  Huddart, RA; Hall, E; Lewis, R; Porta, N; Crundwell, M; Jenkins, PJ; Rawlings, C; Tremlett, J; Campani, L; Hendron, C; Hussain, SA; James, ND; BC2001 Investigators (2020-02)

  BACKGROUND:BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant ...
• Planar Minimization Diagrams via Subdivision with Applications to Anisotropic Voronoi Diagrams 

  Bennett, H; Papadopoulou, E; Yap, C (2016-08)
• Examining the sources of occupational stress in an emergency department. 

  Basu, S; Yap, C; Mason, S (2016-12)

  Previous work has established that health care staff, in particular emergency department (ED) personnel, experience significant occupational stress but the underlying stressors have not been well quantified. Such data ...
• Implementing the EffTox dose-finding design in the Matchpoint trial. 

  Brock, K; Billingham, L; Copland, M; Siddique, S; Sirovica, M; Yap, C (2017-07-20)

  The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation ...
• Embracing model-based designs for dose-finding trials. 

  Love, SB; Brown, S; Weir, CJ; Harbron, C; Yap, C; Gaschler-Markefski, B; Matcham, J; Caffrey, L; McKevitt, C; Clive, S; Craddock, C; Spicer, J; Cornelius, V (2017-07)

  BACKGROUND:Dose-finding trials are essential to drug development as they establish recommended doses for later-phase testing. We aim to motivate wider use of model-based designs for dose finding, such as the continual ...
• Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. 

  Harrison, CN; Mead, AJ; Panchal, A; Fox, S; Yap, C; Gbandi, E; Houlton, A; Alimam, S; Ewing, J; Wood, M; Chen, F; Coppell, J; Panoskaltsis, N; Knapper, S; Ali, S; Hamblin, A; Scherber, R; Dueck, AC; Cross, NCP; Mesa, R; McMullin, MF (2017-10)

  Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis, and leukemia. Patients resistant/intolerant ...

View more